AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Epidermolysis Bullosa

Recent research efforts aimed at curing Epidermolysis Bullosa.

Last updated

Epidermolysis Bullosa

Overview

Epidermolysis bullosa (EB) is a group of inherited disorders in which the skin, and sometimes the lining of the mouth, eyes, digestive tract, and other organs, blisters or tears after very minor friction. The severity ranges from relatively localized blistering in some forms of EB simplex to life-threatening, widespread wounds in severe junctional and recessive dystrophic EB (RDEB). Prognosis therefore varies widely: mild forms may improve or remain manageable over time, whereas severe forms can cause infection, malnutrition, scarring, hand and esophageal deformities, and a high risk of aggressive squamous-cell skin cancer. EB diagnosis and treatment (aad.org)

Standard care remains intensive, lifelong multidisciplinary support: prevention of friction injuries; gentle cleansing and non-adherent dressings; control of pain, itch, infection, anemia, and nutrition; rehabilitation and surgery when needed; and surveillance for complications, particularly skin cancer in RDEB. In the United States, wound-directed products now include the topical gene therapy beremagene geperpavec (Vyjuvek), birch-triterpene gel for eligible EB wounds, and the autologous gene-modified skin-sheet therapy prademagene zamikeracel (Zevaskyn) for RDEB wounds; none corrects EB throughout the body. EB diagnosis and treatment (aad.org)

Scope of Recent Research (2020–present)

Research activity since 2020 has shifted EB from supportive care alone toward molecularly targeted treatment, especially replacement of missing structural proteins, gene-modified skin grafts, and precise gene editing. The strongest clinical progress has occurred in dystrophic EB caused by variants in COL7A1, which encodes type VII collagen, while approaches for dominant EB simplex and junctional EB remain earlier in development. The field has produced approved local gene therapies, but a body-wide, permanent cure that addresses skin, mucosal disease, scarring, inflammation, and cancer risk is not yet available. Gene-editing strategies for EB (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The most consequential advance has been in vivo gene replacement for dystrophic EB. Vyjuvek is a non-replicating herpes simplex virus type 1 vector applied to wounds to deliver a functional COL7A1 gene and enable local production of type VII collagen. The FDA first approved it on May 19, 2023 for patients aged 6 months and older with COL7A1-related dystrophic EB; a later September 12, 2025 approval expanded the labeled population to include patients younger than 6 months and allowed home application by trained caregivers. In the pivotal controlled trial, treated wounds closed completely more often than placebo-treated wounds at six months, but the treatment is wound-specific and requires repeated administration rather than permanently correcting a patient’s skin stem-cell population. FDA approval of Vyjuvek Vyjuvek approval expansion (fda.gov)

A second landmark is ex vivo gene-modified autologous skin replacement. Zevaskyn, approved by the FDA on April 28, 2025, is made from a person’s own skin cells after laboratory insertion of a functional COL7A1 copy using a replication-incompetent retroviral vector; the corrected cells are expanded into sheets and surgically placed on chronic RDEB wounds. In the randomized, within-patient VIITAL study, 81% of treated wounds achieved at least 50% healing at six months versus 16% of control wounds, with a larger average reduction in pain. This is closer to a durable local correction than weekly topical gene delivery because it implants gene-modified epidermal cells, although it is approved for selected wounds rather than all affected skin or internal tissues. Zevaskyn prescribing information FDA Zevaskyn product page (fda.gov)

Gene editing is advancing toward mutation-specific, potentially lasting therapies. In 2024, researchers used allele-specific CRISPR-Cas9 editing in patient-derived epidermal stem cells to disrupt a disease-causing dominant KRT14 allele in EB simplex while preserving the healthy copy; edited cells restored a normal keratin network and retained regenerative stem-cell properties in preclinical testing. In 2026, a separate preclinical study reported adenine-base editing of selected COL7A1 nonsense variants in RDEB patient keratinocytes and fibroblasts, restoring type VII collagen expression and generating edited skin equivalents for transplantation studies. These experiments are promising proof-of-concept work, not yet established human treatments, and each platform must demonstrate comprehensive off-target, tumorigenicity, and durability safety before clinical translation. Allele-specific CRISPR editing in EB simplex Base-edited RDEB skin equivalents (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

Krystal Biotech’s beremagene geperpavec program progressed from a phase 1/2 study of 12 participants to the pivotal phase 3 GEM-3 study in dystrophic EB. The phase 3 trial used a within-patient design, comparing matched wounds treated with the gene therapy or placebo, and supported FDA approval. Vyjuvek remains a clinically important advance because it provides local COL7A1 replacement without integrating into the patient’s genome, but its intended use is repeated treatment of wounds rather than a one-time cure. Phase 1/2 beremagene geperpavec study FDA approval of Vyjuvek (clinicaltrials.gov)

Abeona Therapeutics’ phase 3 VIITAL program produced the data supporting Zevaskyn’s approval for RDEB wounds. By contrast, the investigator-led MissionEB phase 3 trial of intravenous umbilical-cord-derived mesenchymal stromal cells in children with RDEB found no improvement in its primary disease-severity endpoint at three months, despite no treatment-related serious adverse events. This negative result is informative: broadly anti-inflammatory or regenerative cell infusions may be safe, but they have not yet shown that they can reliably correct the structural defect driving RDEB. Zevaskyn prescribing information MissionEB phase 3 trial (fda.gov)

Methodologies and Scientific Approaches

EB cure research typically begins with genetic diagnosis and patient-derived keratinocytes, fibroblasts, or induced pluripotent stem cells. Scientists test whether a therapy restores the missing protein—such as type VII collagen—at the basement-membrane zone, rebuilds anchoring fibrils that bind epidermis to dermis, improves mechanical strength in three-dimensional engineered skin, and maintains long-lived epidermal stem cells. Researchers also use animal graft models, genomic sequencing to assess unintended edits or vector integration, and standardized wound photographs, pain measures, and disease-severity scores in trials. Zevaskyn prescribing information NIAMS skin research program (fda.gov)

Leading Institutions and Funding

Major academic contributors include EB House Austria at Paracelsus Medical University Salzburg, the Centre for Regenerative Medicine “Stefano Ferrari” at the University of Modena and Reggio Emilia, Instituto de Investigación Sanitaria Fundación Jiménez Díaz and collaborating centers in Spain, Great Ormond Street Hospital and King’s College London in the United Kingdom, and U.S. EB specialty centers. Commercial translation has been led prominently by Krystal Biotech and Abeona Therapeutics, while the National Institute of Arthritis and Musculoskeletal and Skin Diseases supports research on skin structural proteins, extracellular matrix biology, disease models, and translational technologies relevant to EB. Gene-editing strategies for EB NIAMS skin research program (pubmed.ncbi.nlm.nih.gov)

Patient-led organizations are especially important in this rare disease. DEBRA organizations fund basic and translational EB projects internationally; DEBRA UK offers pilot grants of up to £15,000, and EB Research Partnership funds commercially translatable projects across gene, cell, cancer, pain, and itch research. MissionEB itself was funded through the National Research Collaboration Programme—an NHS England and National Institute for Health and Care Research partnership—under award NIHR 127963, with Cure EB support. DEBRA UK research funding EB Research Partnership funding MissionEB phase 3 trial (debra.org.uk)

Strengths, Limitations, and Challenges

The field’s major strength is that EB is genetically defined and the skin is accessible: cells can be sampled, corrected outside the body, tested, and grafted back, while wounds can be directly treated and measured. The approvals of Vyjuvek and Zevaskyn demonstrate that restoration of type VII collagen can meaningfully improve healing in dystrophic EB wounds. However, disease heterogeneity means that one product cannot cure all EB types or mutations; local therapies do not address the full skin surface, internal epithelial disease, fibrosis, or cancer susceptibility. FDA approval of Vyjuvek FDA Zevaskyn product page (fda.gov)

Key obstacles include achieving safe delivery to enough long-lived skin stem cells, ensuring that corrected skin remains durable under chronic injury, preventing harmful immune responses, and monitoring for cancer risks. For integrating retroviral approaches such as Zevaskyn, the label specifically warns of a potential risk of insertional oncogenesis, even though the available integration analysis did not show preferential insertion into known cancer-associated genes. Complex individualized manufacturing, surgery, specialized treatment centers, repeat dosing for non-integrating therapies, and cost may also limit equitable access. Zevaskyn prescribing information (fda.gov)

Outlook and Future Directions

As of August 8, 2026, EB research has reached an important transitional stage: local gene replacement and gene-corrected skin grafting are clinical realities for some dystrophic EB wounds, but they should be described as disease-modifying treatments rather than complete cures. The next milestones are longer-term safety and durability data for Zevaskyn, broader access and real-world outcomes for Vyjuvek, first-in-human trials of edited autologous epidermal grafts, and approaches that safely treat large skin areas plus mucosal and systemic complications. A true cure will likely require durable correction of patient stem cells, scalable delivery or grafting, and evidence that the intervention reduces lifelong scarring, inflammation, and cancer risk—not simply short-term wound closure. Base-edited RDEB skin equivalents Zevaskyn prescribing information (sciencedirect.com)

References

Don't see your disease? Request a report